[25] 中 华 医 学 会 肝 病 学 分 会 . 肝 硬 化 诊 治 指 南 [J]. 中 华 肝

脏 病 杂 志 , 2019, 27(11) ：846-865. DOI:10.3760/cma.

j.issn.1007-3418.2019.11.008.

[26] de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII - Renewing

consensus in portal hypertension[J]. J Hepatol, 2022, 76(4):959-974.

DOI: 10.1016/j.jhep.2021.12.022.

[27] Wang Q, Zhao H, Deng Y, et al. Validation of Baveno VII criteria for

recompensation in entecavir-treated patients with hepatitis B-related

decompensated cirrhosis[J]. J Hepatol, 2022, 77(6):1564-1572. DOI:

10.1016/j.jhep.2022.07.037.

[28] He Z, Zhou J, Tian Y, et al. Two-year free of complications

during antiviral therapy predicts stable re-compensation

in immediate-treatment HBV-related decompensated

cirrhosis[J]. Scand J Gastroenterol, 2023, 58(4):403-411. DOI:

10.1080/00365521.2022.2132532.

[29] Huppert LA, Walker Z, Li M, et al. Clinical characteristics

and outcomes in patients with metastatic breast cancer and

pseudocirrhosis: a single center retrospective cohort study[J]. Breast

Cancer Res Treat, 2023, 197(1):137-148. DOI: 10.1007/s10549-022-

06771-5.

[30] Zhang X, Song J, Zhang Y, et al. Baveno VII algorithm outperformed

other models in ruling out high-risk varices in individuals with HBV-

related cirrhosis[J]. J Hepatol, 2023, 78(3):574-583. DOI: 10.1016/

j.jhep.2022.10.030.

[31] Chen S, Wang B, Zhou J, et al. A new glutamine synthetase index to

evaluate hepatic lobular restoration in advanced fibrosis during anti-

HBV therapy[J]. J Med Virol, 2023, 95(2):e28555. DOI: 10.1002/

jmv.28555.

[32] Liu YQ, Zhang C, Li JW, et al. An-Luo-Hua-Xian pill improves the

regression of liver fibrosis in chronic hepatitis B patients treated

with entecavir[J]. J Clin Transl Hepatol, 2023, 11(2):304-313. DOI:

10.14218/JCTH.2022.00091.

[33] Rong G, Chen Y, Yu Z, et al. Synergistic effect of biejia-ruangan

on fibrosis regression in patients with chronic hepatitis B treated

with entecavir: a multicenter, randomized, double-blind, placebo-

controlled trial[J]. J Infect Dis, 2022, 225(6):1091-1099. DOI:

10.1093/infdis/jiaa266.

[34] Shi K, Liu Y, Wang X, et al. Adjuvant Fuzheng Huayu capsule

reduces the incidence of hepatocellular carcinoma in patients with

hepatitis B-caused cirrhosis[J]. Evid Based Complement Alternat

Med, 2020, 2020:8826091. DOI: 10.1155/2020/8826091.

[35] Ji D, Chen Y, Bi J, et al. Entecavir plus Biejia-Ruangan compound

reduces the risk of hepatocellular carcinoma in Chinese patients

with chronic hepatitis B[J]. J Hepatol, 2022, 77(6):1515-1524. DOI:

10.1016/j.jhep.2022.07.018.

[36] Dai YK, Fan HN, Huang K, et al. Baseline metabolites could predict

responders with hepatitis B virus-related liver fibrosis for entecavir

or combined with FuzhengHuayu tablet[J]. World J Hepatol, 2023,

15(9):1043-1059. DOI: 10.4254/wjh.v15.i9.1043.

[37] Turco L, Reiberger T, Vitale G, et al. Carvedilol as the new non-

selective beta-blocker of choice in patients with cirrhosis and portal

hypertension[J]. Liver Int, 2023, 43(6):1183-1194. DOI: 10.1111/

liv.15559.

[38] Wang B, Zhou J, Wu X, et al. Carvedilol plus NUC for patients

with HBV-compensated cirrhosis under virological suppression: a

randomized open-label trial[J]. Am J Gastroenterol, 2023 Dec 7.

DOI: 10.14309/ajg.0000000000002569. Epub ahead of print.

[39] Paar M, Fengler VH, Reibnegger G, et al. Determination of binding

characteristics as a measure for effective albumin using different

methods[J]. Biochim Biophys Acta Gen Subj, 2023, 1867(9):130427.

DOI: 10.1016/j.bbagen.2023.130427.

[40] Baldassarre M, Naldi M, Zaccherini G, et al. Determination of

effective albumin in patients with decompensated cirrhosis: clinical

and prognostic implications[J]. Hepatology, 2021, 74(4):2058-2073.

DOI: 10.1002/hep.31798.

[41] Zacharias HD, Kamel F, Tan J, et al. Rifaximin for prevention and

treatment of hepatic encephalopathy in people with cirrhosis[J].

Cochrane Database Syst Rev, 2023, 7(7):CD011585. DOI:

10.1002/14651858.CD011585.pub2.

[42] Noureddin M, Harrison SA. NASH cirrhosis trials and major adverse

liver outcomes: big data needed[J]. J Hepatol, 2023, 78(1):5-7. DOI:

10.1016/j.jhep.2022.10.022.